Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Grifols, S.A. (GRF.MC)

MCE - MCE Delayed Price. Currency in EUR
13.65+0.38 (+2.86%)
At close: 05:35PM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close13.27
Open13.14
Bid13.64 x 0
Ask13.58 x 0
Day's Range13.03 - 13.80
52 Week Range7.82 - 20.28
Volume2,294,995
Avg. Volume1,742,619
Market Cap8.203B
Beta (5Y Monthly)0.42
PE Ratio (TTM)136.45
EPS (TTM)0.10
Earnings DateFeb 28, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 03, 2021
1y Target Est18.71
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for GRF.MC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      Grifols considers selling 2 bln euros worth of assets to cut debt, Cinco Dias says

      Spanish pharmaceutical company Grifols considers selling assets worth about 2 billion euros ($2.12 billion) to cut its debt, Cinco Dias reported on Wednesday, citing unidentified financial sources. The company may sell its Chinese business and its diagnoses unit, Cinco Dias reported. A spokesperson for the company declined to comment though in November Grifols said it was committed to reducing its 9.4 billion net debt.

    • PR Newswire

      Grifols receives FDA clearance for AlphaID™ At Home, the first free service for U.S. consumers to determine their risk for alpha-1

      Grifols (MCE: GRF) (MCE:GRF.P) (NASDAQ:GRFS), a global leader in plasma-derived medicines and innovative diagnostic solutions, today announced that its AlphaID™ At Home Genetic Health Risk Service, the first-ever free direct-to-consumer program in the U.S. to screen for genetic risk of alpha1-antitrypsin deficiency (alpha-1), has been cleared by the U.S. Food and Drug Administration (FDA).

    • Insider Monkey

      10 Best Pharma Stocks To Buy Now

      In this article, we discuss the 10 best pharma stocks to buy now. If you want to see more stocks in this selection, check out the 5 Best Pharma Stocks To Buy Now. With a compound annual growth rate (CAGR) of 9.1%, the global pharmaceuticals industry is projected to expand to $1587.1 billion in 2022 from […]

    Advertisement
    Advertisement